April 29, 2025 /PRNewswire/ -- Sumitomo Pharma America ... Most common adverse events were urinary tract infection (4.0%), headache (2.7%), dizziness (2.2%) and diarrhea (2.0%).

The study, conducted by researchers at Mzuzu University and published in the National Library of Medicine, found a UTI prevalence of 48.5 per cent among women assessed at Malawi’s Zomba Central ...

Japanese drugmaker Shionogi said on Wednesday that it will acquire Torii Pharmaceutical , a subsidiary of Japan Tobacco , for ...

Teva Pharmaceutical Industries reported a larger than expected rise in first-quarter profit, helped by strong sales gains for ...

The pharmaceutical industry has a crucial role in modern healthcare, but it also has a significant environmental footprint. From large-scale solvent use and carbon emissions to water pollution and ...

HERZLIYA, Israel and CALGARY, AB, May 6, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the ...

Susquehanna analyst Charles Minervino maintained a Buy rating on Patterson-UTI (PTEN – Research Report) yesterday and set a price target of $9.00. The company’s shares closed yesterday at $6.10.

COPENHAGEN, Denmark, May 01, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the first quarter ended March 31, 2025, and provided a business update.

RBC Capital lowered the firm’s price target on Patterson-UTI (PTEN) to $9.50 from $11 and keeps an Outperform rating on the shares as part of a broader research note on Oil & Gas Equipment ...

TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME ...

"We are excited to enter the next phase of Ousia Pharma's journey, advancing our groundbreaking platform towards clinical development," said Anders B. Klein, PhD, CEO of Ousia Pharma. "The strong ...

BERLIN, May 05, 2025--(BUSINESS WIRE)--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of ...